Orthofix Medical Q4 Earnings Call Highlights

Core Insights - Orthofix reported strong performance in Q4 2025, with significant growth in Bone Growth Therapies and U.S. Limb Reconstruction, marking the eighth consecutive quarter of adjusted EBITDA growth [6] Sales Performance - Total global net sales for Q4 were $218.6 million, reflecting a 3% increase on a pro forma, constant-currency basis, excluding discontinued M6 artificial disc product lines [4] - The top 30 U.S. distributor partners contributed to a 25% year-over-year growth in net sales for Q4, with over 75% of U.S. net sales driven by these partners by Q4 2025 [1] Segment Performance - Global limb reconstruction net sales reached $38.0 million, driven by an 8% growth in the U.S. [2] - Bone Growth Therapies achieved Q4 net sales of $68.3 million, up 7%, benefiting from increased utilization and higher prescribing velocity [2] - Global spinal implants, biologics, and enabling technologies reported Q4 net sales of $112.3 million, supported by targeted distributor transitions [3] Product Developments - Orthofix plans to launch the VIRATA Spinal Fixation System in the second half of 2026, integrating it with the 7D navigation platform [7] - The company expects to introduce over a dozen products in the next 18 months, focusing on automation enhancements and technology-enabled advancements [9] Financial Metrics - Q4 pro forma non-GAAP adjusted gross margin was 71.4%, with a Q4 adjusted EBITDA of $29.2 million, representing 13.4% of net sales [10][11] - Free cash flow for Q4 was $16.8 million, with total cash at the end of the quarter amounting to $85.1 million [11] Future Guidance - For 2026, Orthofix guided net sales of $850 million to $860 million, implying approximately 5.5% pro forma constant-currency growth [12] - The company anticipates positive free cash flow for 2026, excluding potential legal settlements, and expects an adjusted gross margin of approximately 72.5% [13]